Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 76 articles:
HTML format
Text format



Single Articles


    May 2017
  1. KEATING JJ, Runge JJ, Singhal S, Nims S, et al
    Intraoperative near-infrared fluorescence imaging targeting folate receptors identifies lung cancer in a large-animal model.
    Cancer. 2017;123:1051-1060.
    PubMed     Text format     Abstract available


    January 2017
  2. REYNOLDS JP, Zhou Y, Jakubowski MA, Wang Z, et al
    Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples.
    Cancer. 2017 Jan 13. doi: 10.1002/cncy.21812.
    PubMed     Text format     Abstract available


  3. PRINTZ C
    FDA approves breakthrough immunotherapy for patients with non-small-cell lung cancer.
    Cancer. 2017;123:191.
    PubMed     Text format    


    September 2016
  4. SANBORN RE, Patel JD, Masters GA, Jayaram N, et al
    A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
    Cancer. 2016 Sep 1. doi: 10.1002/cncr.30287.
    PubMed     Text format     Abstract available


    August 2016
  5. LAMPSON BL, Nishino M, Dahlberg SE, Paul D, et al
    Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.
    Cancer. 2016 Aug 15. doi: 10.1002/cncr.30270.
    PubMed     Text format     Abstract available


    July 2016
  6. PETERS EN, Warren GW, Sloan JA, Marshall JR, et al
    Tobacco assessment in completed lung cancer treatment trials.
    Cancer. 2016 Jul 26. doi: 10.1002/cncr.30223.
    PubMed     Text format    


  7. MILLER JA, Kotecha R, Suh JH
    Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer.
    Cancer. 2016 Jul 8. doi: 10.1002/cncr.30188.
    PubMed     Text format    


  8. HALASZ LM, Uno H, Punglia RS
    Reply to comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer.
    Cancer. 2016 Jul 8. doi: 10.1002/cncr.30187.
    PubMed     Text format    


    June 2016
  9. LIM SH, Sun JM, Choi YL, Kim HR, et al
    Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30135.
    PubMed     Text format     Abstract available


  10. ERSEK JL, Eberth JM, McDonnell KK, Strayer SM, et al
    Knowledge of, attitudes toward, and use of low-dose computed tomography for lung cancer screening among family physicians.
    Cancer. 2016 Jun 13. doi: 10.1002/cncr.29944.
    PubMed     Text format     Abstract available


    May 2016
  11. BELANI CP, Dahlberg SE, Rudin CM, Fleisher M, et al
    Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).
    Cancer. 2016 May 10. doi: 10.1002/cncr.30062.
    PubMed     Text format     Abstract available


    April 2016
  12. HALASZ LM, Uno H, Hughes M, D'Amico T, et al
    Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer.
    Cancer. 2016 Apr 18. doi: 10.1002/cncr.30009.
    PubMed     Text format     Abstract available


  13. GONCALVES PH, Peterson SL, Vigneau FD, Shore RD, et al
    Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data.
    Cancer. 2016 Apr 8. doi: 10.1002/cncr.30000.
    PubMed     Text format     Abstract available


    March 2016
  14. OU W, Li N, Wang SY, Li J, et al
    Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
    Cancer. 2016;122:740-7.
    PubMed     Text format     Abstract available


  15. MOR V, Joyce NR, Cote DL, Gidwani RA, et al
    The rise of concurrent care for veterans with advanced cancer at the end of life.
    Cancer. 2016;122:782-90.
    PubMed     Text format     Abstract available


    February 2016
  16. ARMSTRONG K, Kim JJ, Halm EA, Ballard RM, et al
    Using lessons from breast, cervical, and colorectal cancer screening to inform the development of lung cancer screening programs.
    Cancer. 2016 Feb 29. doi: 10.1002/cncr.29937.
    PubMed     Text format     Abstract available


  17. FUCITO LM, Czabafy S, Hendricks PS, Kotsen C, et al
    Pairing smoking-cessation services with lung cancer screening: A clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco.
    Cancer. 2016 Feb 24. doi: 10.1002/cncr.29926.
    PubMed     Text format     Abstract available


  18. GUIJARRO-MUNOZ I, Roarty EB, Heymach JV
    Bevacizumab beyond disease progression for advanced non-small cell lung cancer: Does persistence have its rewards?
    Cancer. 2016 Feb 1. doi: 10.1002/cncr.29894.
    PubMed     Text format    


  19. TAKEDA M, Yamanaka T, Seto T, Hayashi H, et al
    Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
    Cancer. 2016 Feb 1. doi: 10.1002/cncr.29893.
    PubMed     Text format     Abstract available


  20. TEVAARWERK AJ, Lee JW, Terhaar A, Sesto ME, et al
    Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study.
    Cancer. 2016;122:438-46.
    PubMed     Text format     Abstract available


    January 2016
  21. LITZELMAN K, Kent EE, Rowland JH
    Social factors in informal cancer caregivers: The interrelationships among social stressors, relationship quality, and family functioning in the CanCORS data set.
    Cancer. 2016;122:278-86.
    PubMed     Text format     Abstract available



  22. Xiu-Yi Zhi, Jin-Ming Yu, and Yuan-Kai Shi. Chinese Guidelines on the Diagnosis and Treatment of Primary Lung Cancer (2015 Version). Cancer. 2015;121:3165-3181.
    Cancer. 2016;122:162.
    PubMed     Text format    


    December 2015
  23. VILLALONA-CALERO MA, Lam E, Otterson GA, Zhao W, et al
    Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
    Cancer. 2015 Dec 28. doi: 10.1002/cncr.29856.
    PubMed     Text format     Abstract available


  24. BUNN PA JR, Gaspar LE, Weyant MJ, Mitchell JD, et al
    Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer.
    Cancer. 2015 Dec 23. doi: 10.1002/cncr.29797.
    PubMed     Text format    


  25. STEUER CE, Behera M, Berry L, Kim S, et al
    Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
    Cancer. 2015 Dec 22. doi: 10.1002/cncr.29812.
    PubMed     Text format     Abstract available


    November 2015
  26. GREM JL, Kos ME, Evande RE, Meza JL, et al
    A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
    Cancer. 2015;121:3862-8.
    PubMed     Text format     Abstract available


  27. TRAEGER L, McDonnell TM, McCarty CE, Greer JA, et al
    Nursing intervention to enhance outpatient chemotherapy symptom management: Patient-reported outcomes of a randomized controlled trial.
    Cancer. 2015;121:3905-13.
    PubMed     Text format     Abstract available


    October 2015
  28. PRINTZ C
    Immunotherapy drug improves survival of patients with squamous non-small cell lung cancer.
    Cancer. 2015;121:3562-3.
    PubMed     Text format    


  29. KOLLER M, Warncke S, Hjermstad MJ, Arraras J, et al
    Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development.
    Cancer. 2015 Oct 9. doi: 10.1002/cncr.29682.
    PubMed     Text format     Abstract available


  30. BEHERA M, Ragin C, Kim S, Pillai RN, et al
    Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.
    Cancer. 2015 Oct 6. doi: 10.1002/cncr.29674.
    PubMed     Text format     Abstract available


    September 2015
  31. FERNANDO HC, Dupuy DE
    Reply to defining the role of radiofrequency ablation and stereotactic ablative radiotherapy in patients with high-risk, early-stage non-small cell lung cancer.
    Cancer. 2015 Sep 30. doi: 10.1002/cncr.29699.
    PubMed     Text format    


  32. LOUIE AV, Siva S, Senan S
    Defining the role of radiofrequency ablation and stereotactic ablative radiotherapy in patients with high-risk, early-stage non-small cell lung cancer.
    Cancer. 2015 Sep 30. doi: 10.1002/cncr.29698.
    PubMed     Text format    


  33. HOWARD DH, Richards TB, Bach PB, Kegler MC, et al
    Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening.
    Cancer. 2015 Sep 15. doi: 10.1002/cncr.29677.
    PubMed     Text format     Abstract available


  34. NAIDOO J, Sima CS, Rodriguez K, Busby N, et al
    Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
    Cancer. 2015;121:3212-20.
    PubMed     Text format     Abstract available


  35. NANDA RH, Liu Y, Gillespie TW, Mikell JL, et al
    Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis.
    Cancer. 2015 Sep 8. doi: 10.1002/cncr.29640.
    PubMed     Text format     Abstract available


  36. BISHOP AJ, Ensor J, Moulder SL, Shaitelman SF, et al
    Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.
    Cancer. 2015 Sep 8. doi: 10.1002/cncr.29681.
    PubMed     Text format     Abstract available


  37. MAIN BG, McNair AG, Blazeby JM
    Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer.
    Cancer. 2015 Sep 3. doi: 10.1002/cncr.29673.
    PubMed     Text format    


  38. WINNER M, Kim Y, Pawlik TM
    Reply to patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer.
    Cancer. 2015 Sep 3. doi: 10.1002/cncr.29671.
    PubMed     Text format    



  39. Special issue on lung cancer in China.
    Cancer. 2015;121 Suppl 17:viii-xii.
    PubMed     Text format    


  40. ZHI XY, Yu JM, Shi YK
    Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version).
    Cancer. 2015;121 Suppl 17:3165-81.
    PubMed     Text format    


  41. HU J, Qian GS, Bai CX
    Chinese consensus on early diagnosis of primary lung cancer (2014 version).
    Cancer. 2015;121 Suppl 17:3157-64.
    PubMed     Text format     Abstract available


  42. NI J, Liu DY, Hu B, Li C, et al
    Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer.
    Cancer. 2015;121 Suppl 17:3146-56.
    PubMed     Text format     Abstract available


  43. LI MY, Yuan HL, Ko FW, Wu B, et al
    Antineoplastic effects of 15(S)-hydroxyeicosatetraenoic acid and 13-S-hydroxyoctadecadienoic acid in non-small cell lung cancer.
    Cancer. 2015;121 Suppl 17:3130-45.
    PubMed     Text format     Abstract available


  44. LIAO C, Yu ZB, Meng G, Wang L, et al
    Association between Th17-related cytokines and risk of non-small cell lung cancer among patients with or without chronic obstructive pulmonary disease.
    Cancer. 2015;121 Suppl 17:3122-9.
    PubMed     Text format     Abstract available


  45. YANG DW, Zhang Y, Hong QY, Hu J, et al
    Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
    Cancer. 2015;121 Suppl 17:3113-21.
    PubMed     Text format     Abstract available


  46. ZHI XY, Zou XN, Hu M, Jiang Y, et al
    Increased lung cancer mortality rates in the Chinese population from 1973-1975 to 2004-2005: An adverse health effect from exposure to smoking.
    Cancer. 2015;121 Suppl 17:3107-12.
    PubMed     Text format     Abstract available


  47. LIU SY, Mok T, Wu YL
    Novel targeted agents for the treatment of lung cancer in China.
    Cancer. 2015;121 Suppl 17:3089-96.
    PubMed     Text format     Abstract available


  48. HONG QY, Wu GM, Qian GS, Hu CP, et al
    Prevention and management of lung cancer in China.
    Cancer. 2015;121 Suppl 17:3080-8.
    PubMed     Text format     Abstract available


  49. GOU LY, Niu FY, Wu YL, Zhong WZ, et al
    Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population.
    Cancer. 2015;121 Suppl 17:3069-79.
    PubMed     Text format     Abstract available


  50. RAMALINGAM SS, Khuri FR
    Lung cancer in China: The new frontier?
    Cancer. 2015;121 Suppl 17:3058-60.
    PubMed     Text format    


  51. VEERARAGHAVAN S, Ramalingam SS, Khuri FR
    Early detection of lung cancer in China: The immediate imperative.
    Cancer. 2015;121 Suppl 17:3055-7.
    PubMed     Text format    


  52. KHURI FR
    An overview of Cancer's special issue on lung cancer in China.
    Cancer. 2015;121 Suppl 17:3049-51.
    PubMed     Text format    


  53. EXTERMANN M, Reich RR, Sehovic M
    Chemotoxicity recurrence in older patients: Risk factors and effectiveness of preventive strategies-a prospective study.
    Cancer. 2015;121:2984-92.
    PubMed     Text format     Abstract available


  54. CUMMINGS KM, Gustafson JW Jr, Sales DJ, Khuri FR, et al
    Business as usual is not acceptable.
    Cancer. 2015;121:2864-5.
    PubMed     Text format    


  55. CHEN ZM, Peto R, Iona A, Guo Y, et al
    Emerging tobacco-related cancer risks in China: A nationwide, prospective study of 0.5 million adults.
    Cancer. 2015;121 Suppl 17:3097-106.
    PubMed     Text format     Abstract available


  56. PASKETT ED, Bernardo BM, Khuri FR
    Tobacco and China: The worst is yet to come.
    Cancer. 2015;121 Suppl 17:3052-4.
    PubMed     Text format    


    August 2015
  57. NAYAK L, DeAngelis LM, Robins HI, Govindan R, et al
    Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.
    Cancer. 2015 Aug 26. doi: 10.1002/cncr.29636.
    PubMed     Text format     Abstract available


  58. PRINTZ C
    Off the mark: Current lung cancer screening guidelines miss those most at risk.
    Cancer. 2015;121:2477-8.
    PubMed     Text format    


  59. OU SH
    Darkness before dawn, but will the sun always rise?
    Cancer. 2015;121:2514-6.
    PubMed     Text format    


    July 2015
  60. SUN V, Grant M, Koczywas M, Freeman B, et al
    Effectiveness of an interdisciplinary palliative care intervention for family caregivers in lung cancer.
    Cancer. 2015 Jul 6. doi: 10.1002/cncr.29567.
    PubMed     Text format     Abstract available


    June 2015
  61. DUPUY DE, Fernando HC, Hillman S, Ng T, et al
    Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial.
    Cancer. 2015 Jun 19. doi: 10.1002/cncr.29507.
    PubMed     Text format     Abstract available


  62. DONINGTON JS
    Radiofrequency ablation in high-risk stage I non-small cell lung cancer.
    Cancer. 2015 Jun 19. doi: 10.1002/cncr.29501.
    PubMed     Text format    


  63. KIM Y, Winner M, Page A, Tisnado DM, et al
    Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer.
    Cancer. 2015 Jun 19. doi: 10.1002/cncr.29530.
    PubMed     Text format     Abstract available


  64. PRINTZ C
    Lung cancer new leading cause of death for women in developed countries: Data reflects increased rates of smoking.
    Cancer. 2015;121:1911-1912.
    PubMed     Text format    


  65. YU HA, Sima CS, Hellmann MD, Naidoo J, et al
    Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
    Cancer. 2015;121:2078-82.
    PubMed     Text format     Abstract available


    May 2015
  66. RECKAMP KL, Koczywas M, Cristea MC, Dowell JE, et al
    Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
    Cancer. 2015 May 29. doi: 10.1002/cncr.29480.
    PubMed     Text format     Abstract available


  67. GADGEEL SM
    Cyclooxygenase 2 inhibition in patients with non-small cell lung cancer: Is this still a valid target for therapy?
    Cancer. 2015 May 29. doi: 10.1002/cncr.29479.
    PubMed     Text format    


  68. PRINTZ C
    Smoking still causes significant number of cancer deaths.
    Cancer. 2015;121:1531.
    PubMed     Text format    


  69. DEEKEN JF, Wang H, Subramaniam D, He AR, et al
    A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
    Cancer. 2015;121:1645-53.
    PubMed     Text format     Abstract available


    April 2015
  70. KENZIK KM, Ganz PA, Martin MY, Petersen L, et al
    How much do cancer-related symptoms contribute to health-related quality of life in lung and colorectal cancer patients? A report from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium.
    Cancer. 2015 Apr 17. doi: 10.1002/cncr.29415.
    PubMed     Text format     Abstract available


  71. PISU M, Kenzik KM, Oster RA, Drentea P, et al
    Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: another long-term effect of cancer?
    Cancer. 2015;121:1257-64.
    PubMed     Text format     Abstract available


  72. HOBBS GS, Landrum MB, Arora NK, Ganz PA, et al
    The role of families in decisions regarding cancer treatments.
    Cancer. 2015;121:1079-87.
    PubMed     Text format     Abstract available


    February 2015
  73. DEAN JB, Dome JS
    Reply to Wilms tumor and breast cancer.
    Cancer. 2015 Feb 24. doi: 10.1002/cncr.29281.
    PubMed     Text format    


  74. LEHRER S, Rosenzweig KE
    Wilms tumor and breast cancer.
    Cancer. 2015 Feb 24. doi: 10.1002/cncr.29279.
    PubMed     Text format    


  75. BRESLOW NE, Peterson SM, Green DM
    Reply to Wilms tumor and breast cancer.
    Cancer. 2015 Feb 24. doi: 10.1002/cncr.29278.
    PubMed     Text format    


  76. MACK JW, Walling A, Dy S, Antonio AL, et al
    Patient beliefs that chemotherapy may be curative and care received at the end of life among patients with metastatic lung and colorectal cancer.
    Cancer. 2015 Feb 11. doi: 10.1002/cncr.29250.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: